176 related articles for article (PubMed ID: 38777402)
1. Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
Yau K; Cherney DZI; van Raalte DH; Wever BE
Kidney Int; 2024 Jun; 105(6):1168-1172. PubMed ID: 38777402
[No Abstract] [Full Text] [Related]
2. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
Kume S; Packer M
Kidney Int; 2024 Jun; 105(6):1172-1176. PubMed ID: 38777403
[No Abstract] [Full Text] [Related]
3. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
4. Sweet success? SGLT2 inhibitors and diabetes.
Layton AT
Am J Physiol Renal Physiol; 2018 Jun; 314(6):F1034-F1035. PubMed ID: 29357429
[No Abstract] [Full Text] [Related]
5. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
Pecoits-Filho R; Perkovic V
Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
[No Abstract] [Full Text] [Related]
6. SGLT2 inhibitors: not every drug has the same effect.
Staruschenko A
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
[No Abstract] [Full Text] [Related]
7. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
Tuttle KR; Cherney DZ;
Clin J Am Soc Nephrol; 2020 Feb; 15(2):285-288. PubMed ID: 31740570
[No Abstract] [Full Text] [Related]
8. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
Lanthier L; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
[No Abstract] [Full Text] [Related]
9. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.
Scholtes RA; van Baar MJB; Kok MD; Bjornstad P; Cherney DZI; Joles JA; van Raalte DH
Nephrology (Carlton); 2021 May; 26(5):377-390. PubMed ID: 33283420
[TBL] [Abstract][Full Text] [Related]
10. More CREDENCE for SGLT2 Inhibition.
Verma S; Bhatt DL
Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
[No Abstract] [Full Text] [Related]
11. SGLT2 Inhibitors in Diabetic Kidney Disease.
Zoungas S; de Boer IH
Clin J Am Soc Nephrol; 2021 Apr; 16(4):631-633. PubMed ID: 33536241
[No Abstract] [Full Text] [Related]
12. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
13. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
15. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.
Takata T; Isomoto H
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922132
[TBL] [Abstract][Full Text] [Related]
16. Research digest: SGLT2 inhibition in kidney and liver disease.
Preiss D; Sattar N
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):427. PubMed ID: 31103176
[No Abstract] [Full Text] [Related]
17. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
Kashihara N; Kidokoro K; Kanda E
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells.
Morita M; Kanasaki K
Diabetes Metab; 2020 Oct; 46(5):353-361. PubMed ID: 32891754
[TBL] [Abstract][Full Text] [Related]
19. A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
Kume S; Maegawa H
J Diabetes Investig; 2022 May; 13(5):765-767. PubMed ID: 35029051
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
Packer M
Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
